Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Cyclogest 200mg pessaries

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Progesterone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Progesterone
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Cyclogest contains micronised progesterone, which is a natural, female sex hormone, produced in the body. Cyclogest works by adjusting the hormonal balance within the body for the treatment of: x pre-menstrual syndrome which often affects women during the 7 to 10 days before their monthly period. The symptoms of pre-menstrual syndrome include feelings of tension, irritability, depression, headache, breast tenderness, weight gain and bloatedness x post-natal depression which some women get after their baby has been born. Cyclogest can also be used for the prevention of: x preterm birth in high-risk pregnant women with a singleton pregnancy who have previously had a premature baby and/or who may have a problem with the lower end part of their womb, known as a short cervix. 2.

What you need to know before you take it

e Cyclogest

Do not use Cyclogest if you: x are allergic to progesterone or any of the other ingredients of this medicine (listed in section 6), x have unusual vaginal bleeding that has not been evaluated by the doctor, x have known or suspected tumour that is hormone sensitive, x have porphyria disorders (a group of inherited or acquired disorders of certain enzymes), x have or have had blood clots in the legs, lungs, eyes or elsewhere in the body, x currently have or have had severe liver problems. x have a miscarriage and your physician suspects some tissue is still in the uterus or pregnancy outside of the womb. x If your "waters break" during pregnancy. Warnings and precautions Talk to your doctor, pharmacist or nurse before using Cyclogest. Take special care and tell your doctor straight away if you experience any of these symptoms

during treatment or even few days after the last dosage: pains in the calves or chest, a sudden shortness of breath or coughing blood indicating possible clots in the legs, heart, or lungs severe headache or vomiting, dizziness, faintness, or changes in vision or speech, weakness or numbness of an arm or leg indicating possible clots in the brain or eye worsening of depression Check with your doctor or pharmacist before using Cyclogest if you have or ever have had: • liver problems such as jaundice (yellowing of the skin and whites of the eyes) • epilepsy • migraine • asthma • cardiac or renal dysfunction • diabetes If you are taking Cyclogest to prevent preterm birth in a high-risk pregnancy: Your doctor should discuss the benefits, risks and practicalities of all options available with you which have the potential to prevent preterm birth from happening during your pregnancy. You and your doctor should then make a shared decision on which treatment is the most suitable based on your circumstances. If you have a high risk of delivering your baby prematurely before week 37 of pregnancy, Cyclogest may be started between week 16 and 24 of pregnancy and continued until at least week 34 of your pregnancy. If your waters break or have vaginal bleeding while you are using Cyclogest, you must see your doctor or nurse as soon as possible. If these happen during pregnancy, there may be an immediate risk to you and to your baby. Children There is no relevant use of Cyclogest in children. Other medicines and Cyclogest Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is especially important in case you are taking carbamazepine (e.g. to prevent fits, treat certain type of pain or mood disorders), rifampicin (to treat infections) or phenytoin (e.g. to prevent fits or treat certain type of pain) as they may decrease the effectiveness of progesterone. Using other vaginal products at the same time as Cyclogest is used vaginally is not recommended as it is not known if it affects the treatment. Pregnancy and breast-feeding Cyclogest can be used during pregnancy if your doctor has told you that you are at high risk of having your baby prematurely which is earlier than week 37 of pregnancy. Your doctor or nurse should inform you when to start, when to stop and how to use Cyclogest during pregnancy. For further instructions on how to use Cyclogest see Section 3. The risks of congenital (conditions present at birth) anomalies, including genital abnormalities in male or female infants, from exposure to exogenous progesterone during pregnancy have not been fully established. For other use, if you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. This medicine should not be used during breast feeding.

How to take it

Cyclogest Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. For the treatment of premenstrual syndrome and post-natal depression: The recommended dose is 200 mg once a day or 400 mg twice a day by vaginal or rectal insertion. For the prevention of preterm birth in high-risk pregnant women with a singleton pregnancy who have a history of spontaneous preterm birth and/or a short cervix: The recommended dose is 200 mg once a day at bedtime by vaginal insertion, starting between 16 and 24 weeks and continued until at least 34 weeks of pregnancy. The pessary may be inserted into either the vagina or rectum (back passage) depending upon the following certain other conditions. You should insert Cyclogest into the: x vagina if you have: colitis (inflammation of the colon causing frequent attacks of diarrhoea with mucous or blood) problems controlling your bowel movements (faecal incontinence). x –

rectum (back passage) if you have: a vaginal infection (discharge from your vagina) or often have cystitis (a burning pain on passing water) recently given birth to use a barrier method of birth control such as a diaphragm, cap or condom. Such devices may not work properly in the presence of the hard fat from the pessary.

For premenstrual tension start using Cyclogest on day 12 or 14 of your menstrual cycle. This can be planned and marked onto your calendar; day 1 is the first day of your monthly period, counting forward to day 12 or 14 as advised by your doctor. Do not swallow Cyclogest. How to insert Cyclogest Always wash your hands before and after inserting the pessary. To insert into the: Vagina – place the pessary between the lips of the vagina and push the pessary upwards and backwards. You may find it easier to do this if you are lying down or squatting. • Rectum (back passage) – gently push the pessary into the rectum for about one inch. •

Your muscles will hold the pessary in place when it is in far enough. Squeeze your buttocks together for a few seconds. If you use more Cyclogest than you should If you (or someone else) has accidentally swallowed any of the pessaries or you use too many, contact your nearest hospital casualty department or your doctor immediately for advice. If you forget to use Cyclogest If you forget to insert a pessary, do so as soon as you remember, unless it is nearly time for the next dose. Never use two doses together. Remember to use the remaining doses at the correct time. If you stop using Cyclogest Please consult your doctor or pharmacist for advice if you intend to stop or have stopped using Cyclogest. Abrupt discontinuation of progesterone dosing may cause increased anxiety, moodiness, and increased sensibility to seizures.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop using Cyclogest and contact your doctor at once if you have an allergic reaction. Signs may include a skin rash, which may be itchy. Common (may affect up to 1 in 10 people) Drowsiness, stomach discomfort or pain, breast pain Not known (frequency cannot be estimated from the available data) Diarrhoea, soreness in your rectum (back passage), flatulence (wind), changes in your menstrual cycle (you may find that your monthly period will start earlier than usual or it may be delayed), leakage after the pessary has dissolved (this is quite normal when using medicines that are inserted into the vagina or rectum) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or via the Yellow Card app, which can be downloaded from the Apple App Store, or Google Play Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Cyclogest Keep this medicine out of the sight and reach of children. Do not store above 30°C. Do not use this medicine after the expiry date which is stated on the label/carton/bottle. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Cyclogest contains • The active substance (the ingredient that makes the medicine work) is micronised progesterone. Each pessary contains 200mg of the active ingredient. • The other ingredients are hard fat. What Cyclogest looks like and contents of the pack Cyclogest are off-white, torpedo-shaped pessaries. Pack sizes are 15.

Marketing Authorisation Holder L.D. Collins & Co. Ltd. 1st Floor, Gallery Court, 28 Arcadia Avenue, London, N3 2FG, UK. Manufacturer Accord-UK Ltd., Barnstaple, EX32 8NS, UK. Fulton Medicinali S.p.A, Via Marconi, 28/9, 20044-Arese (MI) Italy. This leaflet was last revised in April 2025.

Frequently asked questions about Cyclogest 200mg pessaries

How do I take Cyclogest 200mg pessaries?

Cyclogest 200mg pessaries comes as pessary containing 200mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Cyclogest 200mg pessaries?

The active substance in Cyclogest 200mg pessaries is progesterone.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Cyclogest 200mg pessaries, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Cyclogest 200mg pessaries without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Progesterone (16 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Cyclogest is indicated for the

1) Treatment of premenstrual syndrome, including premenstrual tension and depression.

2) Treatment of puerperal depression.

3) Prevention of preterm birth in high-risk pregnant women with a singleton pregnancy who have a history of spontaneous preterm birth and/or a short cervix of 25 mm or less measured between 16 and 24 weeks of pregnancy (see Section 4.4).

4.2. Posology and method of administration

For the treatment of premenstrual syndrome and puerperal depression:

200mg daily to 400mg twice a day, by vaginal or rectal insertion. For premenstrual syndrome commence treatment on day 14 of menstrual cycle and continue treatment until onset of menstruation. If symptoms are present at ovulation commence treatment on day 12.

For the prevention of preterm birth in high-risk pregnant women with a singleton pregnancy:

200mg administered vaginally once a day at bedtime, starting between 16 and 24 weeks and continued until at least 34 weeks of pregnancy for women with either:

a) A history of spontaneous preterm birth (up to 34+0 weeks of pregnancy) or mid-trimester loss (from 16+0 weeks of pregnancy onwards); or

b) Results from a transvaginal ultrasound scan carried out between 16+0 and 24+0 weeks of pregnancy that show a cervical length of 25 mm or less.

For information on shared decision making, see Section 4.4.

Use in special populations: There is no experience with use of Cyclogest in patients with impaired liver or renal function.

Paediatric population: There is no relevant use of Cyclogest in the paediatric population.

Elderly: No clinical data have been collected in patients over age 65.

4.3. Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Undiagnosed vaginal bleeding (see Section 4.4.).

- Known or suspected progesterone sensitive malignant tumours.

- Porphyria.

- Severe hepatic dysfunction or disease

- Known missed abortion or ectopic pregnancy.

- Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

- Preterm premature rupture of membranes (PPROM) (see Section 4.4.).

4.4. Special warnings and precautions for use

Precautions specific for prevention of preterm birth in high-risk pregnant women with a singleton pregnancy who have a history of spontaneous preterm birth and/or a short cervix:

Before treatment with Cyclogest is initiated:

- The risks and benefits of all options available which have the potential to prevent preterm birth, should be discussed with the patient. Medical practitioner and the patient should then make a shared decision on which treatment is most suitable based on individual circumstances (see section 5.1).

After starting the treatment with Cyclogest during pregnancy:

- Any kind of vaginal bleeding should always be investigated.

- Preterm premature rupture of membranes (PPROM) should be excluded. Should rupture of membranes occur during treatment with Cyclogest 200mg Pessaries, further treatment should be discontinued (see section 4.3).

Cyclogest is not indicated in threatened miscarriage. Treatment should be discontinued in the event of a missed miscarriage.

Cyclogest should be discontinued if any of the following conditions are suspected:

myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis or retinal thrombosis.

Although risk of thromboembolism has been associated with estrogens, a link with progestins remains questionable. Therefore, in women with generally recognised risk factors for thromboembolic events, such as personal or family history, treatment with Cyclogest may further increase the risk. In these women, the benefits of Cyclogest administration need to be weighed against the risks. It should be noted however, that pregnancy itself carries an increased risk of thrombo-embolic events.

Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.

Because progesterone may cause some degree of fluid retention, conditions that might be influenced by this factor (e.g. epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation.

A decrease in glucose tolerance has been observed in a small number of patients on estrogen-progestin combination drugs. The mechanism of this decrease is not known. For this reason, diabetic patients should be carefully observed while receiving progestin therapy.

Progesterone is metabolised in the liver and should be used with caution in patients with hepatic dysfunction.

Cyclogest contains the hormone progesterone which is present in significant concentrations in women during the second half of the menstrual cycle and during pregnancy. This should be borne in mind when treating patients with conditions that may be hormone-sensitive.

Abrupt discontinuation of progesterone dosing may cause increased anxiety, moodiness, and increased sensibility to seizures.

Treatment of premenstrual syndrome and puerperal depression:

Use rectally if barrier methods of contraception are used.

Use rectally if patients suffer from vaginal infection (especially moniliasis) or recurrent cystitis or have recently given birth.

Use vaginally if patients suffer from colitis or faecal incontinence.

4.5. Interaction with other medicinal products and other forms of interaction

Drugs known to induce the hepatic cytochrome-P450-3A4 system (e.g. rifampicin, carbamazepine or phenytoin) may increase the elimination rate and thereby decrease the bioavailability of progesterone.

The effect of concomitant vaginal products on the exposure of progesterone from Cyclogest has not been assessed and is therefore not recommended.

4.6. Fertility, pregnancy and lactation

Pregnancy

Cyclogest should not be used during pregnancy except as indicated during the second and third trimesters of pregnancy in order to prevent preterm birth in high-risk pregnant women with a singleton pregnancy (see section 4.1 for full details). There is limited and inconclusive data on the risk of congenital anomalies, including genital abnormalities in male or female infants, following intrauterine exposure during pregnancy. The rates of congenital anomalies, spontaneous abortion and ectopic pregnancies observed during the clinical trial were comparable with the event rate described in the general population although the total exposure is too low to allow conclusions to be drawn.

Lactation

Progesterone is excreted in human milk and Cyclogest should not be used during breast-feeding.

4.7. Effects on ability to drive and use machines

None known.

4.8. Undesirable effects

Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000), Not known (cannot be estimated from the available data)

SYSTEM ORGAN CLASS

Common

Uncommon

Not known

Nervous system disorder

Somnolence

Gastrointestinal disorders

Abdominal pain, Abdominal discomfort

Diarrhoea and flatulence may occur with rectal administration.

Skin and subcutaneous tissue disorders

Hypersensitivity reactions (e.g. rash, pruritus)

Reproductive system and breast disorders

Breast pain

Menstruation may occur earlier than expected, or, more rarely, menstruation may be delayed.

General disorders and administration site conditions

Soreness, some leakage of the pessary base

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard or via the Yellow Card app, which can be downloaded from the Apple App Store, or Google Play Store.

4.9. Overdose

There is a wide margin of safety with Cyclogest pessaries, but overdosage may produce euphoria or dysmenorrhoea

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • CYCLOVITA 400 mg prescriptionPROGESTERONUM · rectal / vaginal
  • CRINONE 80 mg/g prescriptionPROGESTERONUM · rectal / vaginal

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • LuteinaProgesteronum · rectal / vaginal
  • CIDR 1,38 g wkłady dopochwowe dla bydłaProgesteronum · rectal / vaginal
  • LutinusProgesteronum · rectal / vaginal
  • Prid deltaProgesteronum · rectal / vaginal
  • CrinoneProgesteronum · rectal / vaginal
  • LustorkProgesteronum · rectal / vaginal

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Cyclogest 200mg pessaries. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →